Michael Giordano
Directeur/Bestuurslid bij RAPT THERAPEUTICS, INC.
Vermogen: 36 117 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Christopher Boerner | M | 53 | 9 jaar | |
| Karl Peggs | M | 57 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 jaar |
| Phil Holzer | M | 48 | 11 jaar | |
| Edwin Moses | M | 69 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 jaar |
| Iraj Ali | M | 48 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 jaar |
| Derek DiRocco | M | 43 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 4 jaar |
| Carsten Boess | M | 57 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 4 jaar |
| Brian Wong | M | 52 | 9 jaar | |
| Linda Kozick | F | 66 | 13 jaar | |
| William Rieflin | M | 64 | 9 jaar | |
| Mary Gray | M | 71 | 5 jaar | |
| Kimberly McCutcheon Jablonski | F | - | 21 jaar | |
| Wendye Robbins | M | 63 | 5 jaar | |
| Peter Arduini | M | 59 | 8 jaar | |
| Lori Lyons-Williams | F | 46 | 3 jaar | |
| Rodney Young | M | 61 | 5 jaar | |
| Sergio Quezada | M | 49 | 4 jaar | |
| Louis Schmukler | M | - | 13 jaar | |
| Daniel Hood | M | - | - | |
| Bernhard R. M. Ehmer | M | 69 | 2 jaar | |
| William Perhacs | M | - | 17 jaar | |
| Robert Coutts | M | 40 | 4 jaar | |
| Zack Newman | M | - | 11 jaar | |
| Pete Feldman | M | - |
Oncovalent Therapeutics, Inc.
 Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | 4 jaar |
| Jim Farmer | M | - | 2 jaar | |
| James Taylor | M | - | 2 jaar | |
| Adnan Rahman | M | - | 2 jaar | |
| Michael Listgarten | M | - | 1 jaar | |
| Edward Samuel | M | - | 2 jaar | |
| Tariq Ahmed | M | - | 4 jaar | |
| Shree Patel | M | - | - | |
| Liz Elmhirst | F | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Nipun Davar | M | - | - | |
| Shari L. Geffon | F | - | 2 jaar | |
| Jennifer Nicholson | F | - | 2 jaar | |
| Tim Power | M | - | 18 jaar | |
| Lisa Moore | M | - | 6 jaar | |
| Paul Kassner | M | 58 | 8 jaar | |
| Aljanae Reynolds | M | - | - | |
| Elisa Petris | M | 45 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 jaar |
| Martin Murphy | M | 55 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Rogier Rooswinkel | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
| Julie O'Neill | F | 58 | 3 jaar | |
| Gwen R. Carscadden | F | 62 | 2 jaar | |
| William Ho | M | 58 | 9 jaar | |
| David J. Wustrow | M | 65 | 8 jaar | |
| Sylvia R. Wheeler | F | 63 | - | |
| Dirk Brockstedt | M | 55 | 6 jaar | |
| Dara Henry | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 80 | 80.81% |
| Verenigd Koninkrijk | 19 | 19.19% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Michael Giordano
- Persoonlijk netwerk
